Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin
- 1 March 2009
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 136 (3) , 856-862
- https://doi.org/10.1053/j.gastro.2008.11.037
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Potential for Hepatitis C Virus Resistance to Nitazoxanide or TizoxanideAntimicrobial Agents and Chemotherapy, 2008
- Clinical trial: randomized, double‐blind, placebo‐controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4Alimentary Pharmacology & Therapeutics, 2008
- Hepatitis C genotype 4Hepatology, 2008
- 68 RANDOMIZED CONTROLLED TRIAL OF NITAZOXANIDE-PEGINTERFERON-RIBAVIRIN, NITAZOXANIDE-PEGINTERFERON AND PEGINTERFERON-RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4Journal of Hepatology, 2008
- Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replicationAntiviral Research, 2007
- Antiparasitic Drug Nitazoxanide Inhibits the Pyruvate Oxidoreductases of Helicobacter pylori , Selected Anaerobic Bacteria and Parasites, and Campylobacter jejuniAntimicrobial Agents and Chemotherapy, 2007
- NitazoxanideDrugs, 2007
- Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infectionJournal of Medical Virology, 2005
- Histopathology of Hepatitis C Virus InfectionSeminars in Liver Disease, 1995
- Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis†Hepatology, 1981